Feds crack down on hospice care Medicare fraud: 4 things to know

Federal officials are taking a closer look at potentially fraudulent practices among hospice and nursing home operators, reports The Columbus Dispatch.

Advertisement

Here are four things to know about the issue.

1. The Office of Inspector General found that some hospice providers, physicians and staff members have aggressively recruited patients, including some who aren’t eligible for services, according to the article.

2. An analysis by The Wall Street Journal of Medicare billing records found that between 2005 and 2013, about 107,000 patients were in hospice for an average of nearly 1,000 days spread out over four or more calendar years. The cost to Medicare for those patients, who represent just 1.3 percent of Medicare’s hospice patients, amounted to 14 percent of its overall hospice spending.

3. Some billing practices, including illegally charging for patients who are not near the end of life, have received attention from regulators, reports The Columbus Dispatch. Since 2010, the federal government has tried to recover more than $1 billion from hospices for such reasons, the report states.

4. Federal investigators also have been taking a closer look at hospice owners and executives for fraud, with more than 60 cases prosecuted in 2015, according to The Columbus Dispatch.

 

 

More articles about healthcare legal & regulatory issues:
8 latest False Claims Act settlements
Former Tuomey CEO will pay $1M to settle false claims case
Lawyers: The new player emerging in the health system C-suite

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.